Procleave

Procleave predicts protease substrate cleavage sites by integrating sequence, chemical group-based, and 3D structural features using a conditional random field framework.


Key Features:

  • Integration of Sequence and Structural Data: Utilizes a conditional random field (CRF) framework to combine sequence data with 3D structural features of substrates to enhance cleavage-site prediction.
  • Structural Feature Representation: Applies LOWESS data-smoothing to represent structural features of known cleavage sites as discrete values for model input.
  • Extensive Benchmarking and Validation: Demonstrated high accuracy in identifying cleavage sites through rigorous benchmarking, independent testing, and case studies.

Scientific Applications:

  • Understanding Protease Functions: Aids elucidation of physiological roles of proteases by predicting substrate cleavage sites involved in protein degradation pathways.
  • Therapeutic Target Identification: Suggests potential novel target substrates and corresponding cleavage sites across different proteases relevant to drug discovery.
  • Pharmaceutical Applicability: Informs development of protease inhibitors or modulators by providing predicted cleavage sites for targeted proteolytic processes.

Methodology:

Maps substrates from the MEROPS database onto the Protein Data Bank (PDB) to obtain protein substrates with solved 3D structures; encodes structural parameters of cleavage sites within a CRF alongside sequence and chemical group-based features; represents structural features as discrete values using LOWESS data-smoothing.

Topics

Details

Added:
1/18/2021
Last Updated:
1/27/2021

Operations

Publications

Li F, Leier A, Liu Q, Wang Y, Xiang D, Akutsu T, Webb GI, Smith AI, Marquez-Lago T, Li J, Song J. Procleave: Predicting Protease-Specific Substrate Cleavage Sites by Combining Sequence and Structural Information. Genomics, Proteomics & Bioinformatics. 2020;18(1):52-64. doi:10.1016/j.gpb.2019.08.002. PMID:32413515. PMCID:PMC7393547.

PMID: 32413515
PMCID: PMC7393547
Funding: - Australian Research Council: DP120104460, LP110200333 - National Health and Medical Research Council of Australia: APP1127948, APP1144652, APP490989 - National Institute of Allergy and Infectious Diseases of the National Institutes of Health, USA: R01 AI111965 - Monash University, Australia: 2018-28, 2019-32 - National Institutes of Health, USA: R01 AI111965

Links